Q2 FY2026 EarningsQ2 FY26 results beat consensus across key metrics, with revenue of $2.1M exceeding the $1.3M expected and a narrower GAAP net loss of $(0.25) per share vs. the $(0.27) anticipated. The top-line beat was driven by preclinical collaboration activities with Ono Pharmaceutical, while total operating expenses decreased by $14.3M YoY due to strategic cost discipline. With $153.8M in cash and a runway extended into 2028, the company is well-capitalized to advance its lead candidate FT819 into a potentially registrational Phase 2 trial for lupus nephritis.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Fate Therap(FATE) the Revenue is 2.082 M (+9.18%), Beat estimate;the EBIT is -31.13 M (+15.78%), Beat estimate;the EPS is -0.25 (+13.79%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B9.18%
0.00B33.22%
+0.00B42.40%
EBITExceed expectations
-0.03B15.78%
-0.03B6.49%
+0.00B9.29%
EPSExceed expectations
-0.2513.79%
-0.26827.52%
+0.01826.27%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf